Taken together, these data suggested that PDLIM2 repression contributes to lung cancer immune evasion via repressing MHC-I expression/tumor antigen presentation and T-cell activation to evade CTLs on one hand, and inducing cell growth-related genes to resist CTL cytotoxicity on the other hand. This evidence concerns the gene PDLIM2 and lung carcinoma.